Veradermics, Incorporated

NYSE:MANE Stock Report

Market Cap: US$5.4b

Veradermics Management

Management criteria checks 2/4

Veradermics' CEO is Reid Waldman, appointed in Dec 2022, has a tenure of 3.58 years. total yearly compensation is $8.46M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth $30.48M. The average tenure of the management team and the board of directors is 1 years and 4.8 years respectively.

Key information

Reid Waldman

Chief executive officer

US$8.5m

Total compensation

CEO salary percentage5.32%
CEO tenure3.6yrs
CEO ownership0.6%
Management average tenure1yr
Board average tenure4.8yrs

Recent management updates

No updates

Recent updates

Seeking Alpha • Apr 28

Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis

Summary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Reid Waldman's remuneration changed compared to Veradermics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$99m

Dec 31 2025US$8mUS$450k

-US$83m

Sep 30 2025n/an/a

-US$62m

Dec 31 2024US$812kUS$371k

-US$27m

Compensation vs Market: Reid's total compensation ($USD8.46M) is about average for companies of similar size in the US market ($USD8.35M).

Compensation vs Earnings: Reid's compensation has increased whilst the company is unprofitable.

CEO

Reid Waldman (31 yo)

3.6yrs
Tenure
US$8,455,507
Compensation

Dr. Reid Waldman, M.D., serves as Director at Achieve Life Sciences, Inc. since May 29, 2026. He is co-founder and Director of VeraDermics, Inc. since October 2019 and has been its Chief Executive Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Reid Waldman
CEO & Director3.6yrsUS$8.46m0.56%
$ 30.5m
Dominic Carrano
CFO & Treasurer1.4yrsUS$2.21m0%
$ 0
Timothy Durso
Chief Technical Officerless than a yearUS$3.31m0.56%
$ 30.5m
Michael Greco
General Counsel & Secretary1yrno datano data
Karl Pruss
Senior Director of Manufacturing Sciences & Technologyno datano datano data
Mark Neumann
Chief Commercial & Strategy Officerless than a yearno datano data
Erika Sipperly
Controllerno datano datano data
Michael Smolinski
Vice President of Development & Scientific Operationsno datano datano data
Aron Shapiro
Vice President of Clinical Development & Regulatory Affairsno datano datano data
Brian Trautman
Director of CMC Project Managementno datano datano data
Barbara Szymaszek
Director of Clinical Operationsno datano datano data
Elizabeth Lindemann
Associate Director of Medical Affairsno datano datano data
1.0yrs
Average Tenure
48yo
Average Age

Experienced Management: MANE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Reid Waldman
CEO & Director6.8yrsUS$8.46m0.56%
$ 30.5m
John Childs
Independent Non-Employee Director4.8yrsno data5.27%
$ 285.7m
Patrick Gerald Enright
Independent Non-Employee Director1.6yrsno datano data
David Friedman
Independent Non-Employee Directorless than a yearno datano data
Vladimir Coric
Independent Non-Employee Director4.8yrsUS$7.89k1.56%
$ 84.5m
Katarina Pance
Independent Non-Employee Directorless than a yearno datano data
Jane Grant-Kels
Independent Non-Employee Director4.8yrsno data0.054%
$ 2.9m
4.8yrs
Average Tenure
55yo
Average Age

Experienced Board: MANE's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 19:29
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veradermics, Incorporated is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prakhar AgrawalCantor Fitzgerald & Co.
Geoffrey MeachamCitigroup Inc
Roger SongJefferies LLC